HC Wainwright & Co. Reiterates Buy on Xeris Biopharma Holdings, Maintains $6 Price Target
Portfolio Pulse from richadhand@benzinga.com
HC Wainwright & Co. analyst Oren Livnat has reiterated a 'Buy' rating on Xeris Biopharma Holdings (NASDAQ:XERS) and maintained a $6 price target.
August 09, 2023 | 10:42 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Xeris Biopharma Holdings' stock has been reiterated as a 'Buy' by HC Wainwright & Co. with a maintained price target of $6.
The reiteration of a 'Buy' rating by a reputable analyst like Oren Livnat from HC Wainwright & Co. is a positive signal for Xeris Biopharma Holdings. The maintained price target of $6 also indicates the analyst's confidence in the company's potential. This could lead to increased investor confidence and potentially a short-term increase in the stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100